Role of CXCL16 in BLM-induced epithelial-mesenchymal transition in human A549 cells

Respir Res. 2021 Feb 6;22(1):42. doi: 10.1186/s12931-021-01646-7.

Abstract

Alveolar epithelial cells play an essential role in the initiation and progression of pulmonary fibrosis, and the occurrence of epithelial-mesenchymal transition (EMT) may be the early events of pulmonary fibrosis. Recent studies have shown chemokines are involved in the complex process of EMT, and CXC chemokine ligand 16 (CXCL16) is also associated with many fibrosis-related diseases. However, whether CXCL16 is dysregulated in alveolar epithelial cells and the role of CXCL16 in modulating EMT in pulmonary fibrosis has not been reported. In this study, we found that CXCL16 and its receptor C-X-C motif chemokine receptor 6 (CXCR6) were upregulated in bleomycin induced EMT in human alveolar type II-like epithelial A549 cells. Synergistic effect of CXCL16 and bleomycin in promoting EMT occurrence, extracellular matrix (ECM) excretion, as well as the pro-inflammatory and pro-fibrotic cytokines productions in A549 cells were observed, and those biological functions were impaired by CXCL16 siRNA. We further confirmed that CXCL16 regulated EMT in A549 cells via the TGF-β1/Smad3 pathways. These results indicated that CXCL16 could promote pulmonary fibrosis by promoting the process of EMT via the TGF-β1/Smad3 signaling pathway.

Keywords: CXCL16; Chemokines; Epithelial–mesenchymal transition; Pulmonary fibrosis.

MeSH terms

  • A549 Cells
  • Antibiotics, Antineoplastic / toxicity
  • Bleomycin / toxicity*
  • Chemokine CXCL16 / biosynthesis*
  • Dose-Response Relationship, Drug
  • Epithelial-Mesenchymal Transition / drug effects*
  • Epithelial-Mesenchymal Transition / physiology*
  • Humans

Substances

  • Antibiotics, Antineoplastic
  • CXCL16 protein, human
  • Chemokine CXCL16
  • Bleomycin